Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 315 across all filing types
Latest filing 2017-07-30 Interim / Quarterly Rep…
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 7 pages 369.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'QUARTERLY REPORT – APPENDIX 4C' and references compliance with ASX Listing Rule 4.7B, which pertains to quarterly reporting requirements for entities listed on the Australian Securities Exchange. The content includes detailed operational updates, progress milestones, and a consolidated statement of cash flows for the quarter ended 30 June 2017. The presence of actual financial data such as cash flow statements and operational commentary confirms this is a substantive quarterly financial report rather than a mere announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2017
2017-07-30 English
Appendix 3B - Issue of Options 11 pages 735.3KB
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement from Vectus Biosystems Limited regarding the issuance of options to employees under the company's Employee Incentive Plan. It includes an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) form used for new issue announcements, applications for quotation of additional securities, and agreements. The document discusses the number and terms of options issued, vesting conditions, and compliance with relevant Corporations Act provisions. There is no financial performance data, earnings information, or management discussion of results. The document is not a report but an official announcement of a capital issuance event, specifically the issuance of options and related securities. Therefore, it fits the category of a Capital/Financing Update (CAP).
2017-06-04 English
Appendix 4C - Quarterly Report and Update 6 pages 331.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY REPORT – APPENDIX 4C' and references compliance with ASX Listing Rule 4.7B, which pertains to quarterly reporting requirements for entities listed on the Australian Securities Exchange. The content includes detailed financial data such as consolidated cash flow statements, cash reconciliation, financing facilities, and estimated cash outflows for the next quarter. It also discusses operational updates and progress on research and development activities. The document length is over 13,000 characters, indicating it is a substantive report rather than a brief announcement. The presence of actual financial statements and analysis for the quarter ended 31 March 2017 confirms it is a comprehensive interim/quarterly financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2017
2017-04-27 English
Half Yearly Report and Appendix 4D 19 pages 1.3MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half-Year Report' and references financial results for the half-year ended 31 December 2016. It includes detailed financial data such as condensed consolidated statements of profit or loss, financial position, changes in equity, cash flows, notes to financial statements, directors' report, auditor's review report, and auditor's independence declaration. The presence of these comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document is substantive and not merely an announcement or certification, so it is not classified as RPA or RNS. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). H1 2017
2017-02-27 English
Response to ASX Appendix 4C Query 5 pages 730.3KB
Regulatory Filings Classification · 95% confidence The document is a letter from ASX Compliance to Vectus Biosystems Limited regarding the company's Appendix 4C Quarterly Report for the period ended 31 December 2016. The letter requests detailed information about the company's cash flow, funding plans, and compliance with ASX Listing Rules. The company's response addresses these questions, confirming ongoing negative cash flows, potential fundraising activities, and compliance with listing rules. The document is a regulatory inquiry and response related to a quarterly cash flow report (Appendix 4C), which is a type of interim report but the document itself is not the report; it is a compliance and disclosure communication. It does not contain actual financial statements or substantive financial data but discusses the company's financial condition and compliance. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for compliance-related disclosures and regulatory correspondence that do not fit other categories.
2017-02-12 English
Appendix 4C - quarterly 6 pages 360.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY REPORT – APPENDIX 4C' and references compliance with ASX Listing Rule 4.7B, which pertains to quarterly reporting for entities listed on the Australian Securities Exchange. The content includes detailed financial data such as consolidated cash flow statements for the quarter ended 31 December 2016, commentary on company activities, and estimated cash outflows for the next quarter. The document length is substantial (over 14,000 characters) and contains actual financial statements and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2017
2017-01-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.